• Publications
  • Influence
Functional Characterization and Target Validation of Alternative Complex I of Plasmodium falciparum Mitochondria
ABSTRACT This study reports on the first characterization of the alternative NADH:dehydrogenase (also known as alternative complex I or type II NADH:dehydrogenase) of the human malaria parasiteExpand
  • 111
  • 8
The malaria parasite type II NADH:quinone oxidoreductase: an alternative enzyme for an alternative lifestyle.
The operation of a type II NADH:quinone oxidoreductase (PfNDH2), also known as alternative Complex I, in the mitochondrion of the human malaria parasite, Plasmodium falciparum, has recently beenExpand
  • 70
  • 7
Rapid kill of malaria parasites by artemisinin and semi-synthetic endoperoxides involves ROS-dependent depolarization of the membrane potential
Objectives Artemisinin and artemisinin semi-synthetic derivatives (collectively known as endoperoxides) are first-line antimalarials for the treatment of uncomplicated and severe malaria.Expand
  • 78
  • 6
Antimalarial pharmacology and therapeutics of atovaquone
Atovaquone is used as a fixed-dose combination with proguanil (Malarone) for treating children and adults with uncomplicated malaria or as chemoprophylaxis for preventing malaria in travellers.Expand
  • 80
  • 5
Glycerol: An unexpected major metabolite of energy metabolism by the human malaria parasite
BackgroundMalaria is a global health emergency, and yet our understanding of the energy metabolism of the principle causative agent of this devastating disease, Plasmodium falciparum, remains ratherExpand
  • 51
  • 4
Trichomonas vaginalis and Giardia intestinalis Produce Nitric Oxide and Display NO‐Synthase Activity
TRICHOMONAS vaginalis is a microaerophilic parasite of the human urogenital tract which is the causative agent of the sexually transmitted disease trichomoniasis. In vivo, T. vaginalis is exposed toExpand
  • 11
  • 4
Generation of quinolone antimalarials targeting the Plasmodium falciparum mitochondrial respiratory chain for the treatment and prophylaxis of malaria
There is an urgent need for new antimalarial drugs with novel mechanisms of action to deliver effective control and eradication programs. Parasite resistance to all existing antimalarial classes,Expand
  • 125
  • 3
Inhibiting Plasmodium cytochrome bc1: a complex issue.
The cytochrome bc(1) complex is a key mitochondrial enzyme that catalyses transfer of electrons maintaining the membrane potential of mitochondria. Currently, atovaquone is the only drug in clinicalExpand
  • 81
  • 3
PfCRT and the trans-vacuolar proton electrochemical gradient: regulating the access of chloroquine to ferriprotoporphyrin IX.
It is accepted that resistance of Plasmodium falciparum to chloroquine (CQ) is caused primarily by mutations in the pfcrt gene. However, a consensus has not yet been reached on the mechanism by whichExpand
  • 83
  • 3